BRCA2 and COVID-19: Considering the single-arm trial design, and treatment discontinuation due to COVID-19, further clinical research with a larger sample size is needed to confirm definitively our findings, and moreover more tissue staining should be performed when tissue samples are available to identify further BRCA2, BRINP3, FBXW7, KIT and RB1 mutations in tumor tissues.